|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Collectively, ZINC05463076, ZINC2102846 and ZINC19901103 exhibited significant antitumor activity in human prostate tumors <i>in vitro</i>, by inhibiting EGFR and promoting apoptosis, which suggested a rationale for clinical development in prostate tumor therapy.
|
30405791 |
2018 |
|
Prostatic Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Growth factors activating the ErbB receptors have been described in prostate tumors.
|
22606295 |
2012 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this issue of Science Translational Medicine, Ateeq et al. provide evidence to support a rationale for targeting the SPINK1 protein in the SPINK1+/ETS⁻ subset of prostate tumors and also describe a potential interaction of SPINK1 with epidermal growth factor receptor that could be an additional target for therapeutic intervention.
|
21368221 |
2011 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.
|
19143022 |
2009 |
|
Prostatic Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer.
|
18302229 |
2008 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Marked gene transcript level alterations occur early during radical prostatectomy.
|
17448597 |
2008 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
|
17914592 |
2007 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction.
|
17469127 |
2007 |
|
Prostatic Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
|
17914592 |
2007 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In previous studies we demonstrated that antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha [MR1]), its binding site the epidermal growth factor receptor (EGFR [MR2]), and the anti-apoptosis protein bcl-2 (MR4) are efficacious against prostate tumors.
|
17917084 |
2007 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models.
|
17136230 |
2006 |
|
Prostatic Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models.
|
17136230 |
2006 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
|
15302576 |
2004 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
|
14688027 |
2004 |
|
Prostatic Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
|
15302576 |
2004 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In order to define AR, erbB-1 and erbB-2 in human prostate neoplasms 36 benign prostatic hyperplasia, 46 prostatic carcinoma and 12 normal prostate gland samples were analysed.
|
14654929 |
2004 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
FD137, a nitrosourea appended to a quinazoline ring, was designed to simultaneously block epidermal growth factor receptor (EGFR)-mediated signaling and damage genomic DNA in refractory EGF-dependent prostate tumors.
|
14991862 |
2004 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
We examined the interaction between the ErbB receptors and androgens using the LNCaP androgen-sensitive prostate tumor model.
|
12746839 |
2003 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We examined the interaction between the ErbB receptors and androgens using the LNCaP androgen-sensitive prostate tumor model.
|
12746839 |
2003 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
|
12429632 |
2002 |
|
Prostatic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These studies examined the effect of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ("Iressa")(3) on CWR22 prostate tumors in nude mice.
|
12473602 |
2002 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Inhibition of human pancreatic, renal, breast and prostate tumor xenografts which express different levels of EGFr by ABX-EGF was also achieved.
|
11255078 |
2001 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Although the role of oncogenes and growth factors in prostate carcinoma is still unclear, overexpression of the epidermal growth factor receptor (erbB-1) and the proto-oncogene erbB-2 have been reported in prostate tumors, and erbB-2 related to poor prognosis and distant metastasis.
|
9917515 |
1999 |
|
Prostatic Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These data suggest that up-regulated signaling by EGFR promotes prostate tumor invasiveness secondary to increased cell motility.
|
9815625 |
1997 |